611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Health Sciences
Basic InformationLatest News
AHA News: Statistics Report Offers Snapshot of the Nation's Brain Health – And a Guide to Protecting ItAHA News: Obesity Harms Brain Health Throughout Life – Yet Scientists Don't Know WhyEven a Little Exercise May Help Slow Parkinson'sScientists ID Genes That Make Your ​FingerprintsCould the 'Alzheimer's Gene' Raise Risks for Severe COVID-19?Genes 'Switched On' Much Earlier in Human Embryos Than ThoughtFormaldehyde in the Workplace Tied to Later Brain IssuesAHA News: Making a Lifetime of Good Brain Health a Global PriorityNFL Players Face 4 Times the Odds of ALSCould Gene Therapy Help Cure Sickle Cell Disease?Toxins in Wildfire Smoke May Make Their Way Into BrainMRI Might Spot Concussion-Linked CTE in Living PatientsCertain Blood Thinners Can Raise Risk of 'Delayed' Bleeding After Head InjuryAHA News: Former NFL Players With Lots of Concussions May Have Higher Stroke RiskMore Years Playing Football, More Brain Lesions on MRI: StudyNew Insights Into What Might Drive Parkinson's DiseaseBrain's 'White Matter' Changes in People With AutismWearable Vibration Device May Ease Parkinson's TremorNeurologists' Group Issues New Treatment Guidelines for Early Parkinson'sGene Therapy Could Be Big Advance Against HemophiliaBlood Test Looks at Patients' Whole Genome to Spot Rare Inherited DiseasesSales of Unproven, Unapproved Stem Cell Therapies Are BoomingHow Bilingual Brains Shift Quickly Between LanguagesMouse Study Offers Hope for Gene Therapy Against Parkinson's DiseaseInsomnia Tied to Raised Risk of AneurysmAHA News: Could the Path to Better Brain Health Involve Better Mouth Care?More Americans Are Dying From Parkinson's Disease: StudyTen Years On, Gene Therapy Still Beating Most Cases of 'Bubble Boy' Immune DiseaseResearchers Find Better Way to Fight Breast Cancer That Has Spread to BrainShape, Size of Brain Arteries May Predict Stroke RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Insights Into Genes Driving Epilepsy Could Help With TreatmentFewer American Adults Are Getting Malignant Brain TumorsLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtStroke Prevented His Speech, But Brain Implant Brought It BackWHO Calls for Global Registry of Human Genome EditingScientists Track Spirituality in the Human BrainNew Insights Into How Eating Disorders Alter the BrainGene Differences Could Have Black Patients Undergoing Unnecessary BiopsiesCRISPR Therapy Fights Rare Disease Where Protein Clogs OrgansNew Genetic Insights Into Cause of ALSDeep Brain Stimulation Therapy May Help Parkinson's Patients Long TermAmazon Tribe Could Hold Key to Health of Aging BrainsMan Blind for 40 Years Regains Some Sight Through Gene TherapyNew Insights Into Treating Mild Head Injuries'Ghosts and Guardian Angels': New Insights Into Parkinson's HallucinationsHigher Education Won't Help Preserve the Aging Brain: StudyScientists Create Embryos With Cells From Monkeys, Humans
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

CRISPR Therapy Fights Rare Disease Where Protein Clogs Organs

HealthDay News
by By Alan Mozes HealthDay Reporter
Updated: Jun 29th 2021

new article illustration

TUESDAY, June 29, 2021 (HealthDay News) -- Early research suggests that CRISPR gene-editing technology may some day lead to dramatic relief for patients struggling with amyloidosis, a rare but serious disease that can trigger organ failure.

"There are many different types of amyloidosis," explained study author Dr. Julian Gillmore, a researcher in medicine with the Centre for Amyloidosis and Acute Phase Proteins at University College London and the Royal Free Hospital in London.

But in broad strokes, the Amyloidosis Foundation says the disorder is characterized by the buildup of an abnormal amyloid protein in the bloodstream, which ends up being deposited throughout the body.

The U.S. National Institutes of Health characterizes amyloidosis as an "orphan disease," in reference to its rarity.

Yet, for those struck by the illness, the symptoms can be devastating. Over time, protein buildup leads to the clogging, stiffening and, in some cases, wholesale failure of tissues, nerves, critical organs and muscles.

Stanford Health Care notes that in severe cases, organ transplantation coupled with ongoing chemotherapy may be in order. But even then the optimal end result is management of the illness, rather than a cure.

With an eye towards a more effective treatment, Gillmore's team focused on a specific form of the disorder known as "ATTR amyloidosis" (ATTR), which leads to dangerous elevations of a protein called TTR.

A debilitating, nonhereditary "wild-type" of ATTR has come to be "an increasingly recognized cause of heart failure," Gillmore explained.

But he and his colleagues focused their efforts on an equally debilitating hereditary form of ATTR, which is thought to affect roughly 50,000 patients around the world, primarily targeting either the nerves or the heart.

Hereditary ATTR, he noted, "is associated with a huge disease burden for patients and their carers. As the disease progresses, patients become incontinent of urine and feces, become immobile and confined to a wheelchair or to their bed, and live in constant pain. In addition, patients have the prospect of passing the disease to their children."

The new study enlisted six patients who had previously been diagnosed with hereditary ATTR.

Three were treated with a single infusion of a low-dose version of NTLA-2001, a drug developed by means of a cutting-edge gene-editing therapy called CRISPR.

The other three patients were treated with a high-dose version of the same drug. The study team said that both doses of the treatment were designed to lower circulating concentrations of TTR.

After the one-month mark, the team observed a dramatic lowering of TTR, with only "mild" side effects.

The three patients given the low-dose treatment experienced a 52% drop in TTR (on average), and the three patients in the high-dose group saw an average drop of 87%, the researchers reported.

As a result, Gillmore said that his team concluded that the "new gene-editing therapy is particularly exciting, since it offers patients a prospect of meaningful clinical improvements after [just] a single intravenous administration of the drug."

Still, he cautioned that the findings are still preliminary. "It is still in early-stage human trials at the moment," he stressed. "But it looks extremely promising so far."

Mary O'Donnell, president and CEO of the Amyloidosis Foundation, expressed cautious optimism about the research.

"A treatment that would knock out amyloid protein would be a welcome addition to the current treatments for ATTR patients," she said. "CRISPR would be a major step forward with the ability to knock out TTR, and we look forward to seeing more data from ongoing clinical trials."

Gillmore and his colleagues published their findings June 26 in the New England Journal of Medicine.

More information

There's more on ATTR and other forms of the disorder at the Amyloidosis Foundation.

SOURCES: Julian Gillmore, MD, PhD, researcher in medicine, Centre for Amyloidosis and Acute Phase Proteins, division of medicine, University College London, Royal Free Hospital, London; Mary O'Donnell, BS, president and CEO, Amyloidosis Foundation, Clarkston, Mich.; New England Journal of Medicine, June 26, 2021